Advertisement
IMVT vs XNCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Hold and XNCR is a StrongBuy.
IMVT's Indicator enters downward trend
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 226 similar instances where the Aroon Indicator formed such a pattern. In 194 of the 226 cases the stock moved lower. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
IMVT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Oscillator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMVT as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 33 of 44 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.575) is normal, around the industry mean (3.498). P/E Ratio (-10.865) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
XNCR in upward trend: price rose above 50-day moving average on October 26, 2026
XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 51 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +18.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 188 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XNCR broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.282) is normal, around the industry mean (3.498). P/E Ratio (-16.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMVT | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 55 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 57 | 34 | |
P/E GROWTH RATING 1..100 | 20 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XNCR's Valuation (16) in the Biotechnology industry is in the same range as IMVT (31) in the null industry. This means that XNCR’s stock grew similarly to IMVT’s over the last 12 months.
IMVT's Profit vs Risk Rating (55) in the null industry is somewhat better than the same rating for XNCR (100) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than XNCR’s over the last 12 months.
XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that XNCR’s stock grew similarly to IMVT’s over the last 12 months.
XNCR's Price Growth Rating (34) in the Biotechnology industry is in the same range as IMVT (57) in the null industry. This means that XNCR’s stock grew similarly to IMVT’s over the last 12 months.
IMVT's P/E Growth Rating (20) in the null industry is significantly better than the same rating for XNCR (97) in the Biotechnology industry. This means that IMVT’s stock grew significantly faster than XNCR’s over the last 12 months.
| IMVT | XNCR | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 81% | 4 days ago 68% |
| Stochastic ODDS (%) | 4 days ago 84% | 4 days ago 77% |
| Momentum ODDS (%) | 4 days ago 81% | 4 days ago 68% |
| MACD ODDS (%) | 4 days ago 75% | 4 days ago 77% |
| TrendWeek ODDS (%) | 4 days ago 80% | 4 days ago 78% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 73% |
| Advances ODDS (%) | 6 days ago 76% | 6 days ago 75% |
| Declines ODDS (%) | 8 days ago 81% | 27 days ago 82% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 74% |
| Aroon ODDS (%) | 4 days ago 86% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMVT’s FA Score shows that 2 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
- IMVT’s FA Score: 2 green, 3 red.
- XNCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMVT’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).
- IMVT’s TA Score: 4 bullish, 4 bearish.
- XNCR’s TA Score: 5 bullish, 5 bearish.
Price Growth
IMVT (@Biotechnology) experienced а +4.66% price change this week, while XNCR (@Biotechnology) price change was +19.89% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
IMVT is expected to report earnings on Nov 09, 2026.
XNCR is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMVT and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +7.54% | ||
| ROIV - IMVT | 64% Loosely correlated | +6.17% | ||
| LXEO - IMVT | 50% Loosely correlated | -0.52% | ||
| KURA - IMVT | 48% Loosely correlated | +6.91% | ||
| XNCR - IMVT | 47% Loosely correlated | +4.99% | ||
| SYRE - IMVT | 46% Loosely correlated | +7.53% | ||
More | ||||
XNCR and
Correlation & Price change
A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with KURA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then KURA could also see price increases.
| Ticker / NAME | Correlation To XNCR | 1D Price Change % | ||
|---|---|---|---|---|
| XNCR | 100% | +4.99% | ||
| KURA - XNCR | 53% Loosely correlated | +6.91% | ||
| VCYT - XNCR | 52% Loosely correlated | +0.67% | ||
| DYN - XNCR | 51% Loosely correlated | +4.09% | ||
| ORKA - XNCR | 48% Loosely correlated | +7.12% | ||
| RCUS - XNCR | 48% Loosely correlated | +3.34% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BKLC | 46.91 | 0.17 | +0.36% |
| BNY Mellon US Large Cap Core Equity ETF (BKLC) | |||
| PSCQ | 31.65 | 0.01 | +0.03% |
| Pacer Swan SOS Conservative (October) ETF (PSCQ) | |||
| BPAY | 24.41 | N/A | N/A |
| iShares FinTech Active ETF (BPAY) | |||
| IEUS | 70.37 | -0.96 | -1.35% |
| iShares MSCI Europe Small-Cap ETF (IEUS) | |||
| XRT | 89.50 | -1.57 | -1.72% |
| State Street SPDR S&P Retail ETF (XRT) | |||